Clinical trial results:
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of PF-04965842 Monotherapy in Subjects Aged 12 Years and Older, With Moderate to Severe Atopic Dermatitis

Summary

EudraCT number	2018-001136-21
Trial protocol	BG HU CZ GB DE PL LV
Global end of trial date	13 August 2019

Results information

Result version number	v1 (current)
This version publication date	07 February 2020
First version publication date	07 February 2020

Trial information

Trial identification

Sponsor protocol code	B7451013

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03575871
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	13 August 2019

Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	13 August 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the efficacy of PF-04965842 compared with placebo in subjects aged 12 years and older with moderate to severe AD

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	29 June 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 23
Country: Number of subjects enrolled	United States: 58
Country: Number of subjects enrolled	Australia: 32
Country: Number of subjects enrolled	Bulgaria: 22
Country: Number of subjects enrolled	Canada: 23
Country: Number of subjects enrolled	China: 24
Country: Number of subjects enrolled	Czech Republic: 14
Country: Number of subjects enrolled	Germany: 39
Country: Number of subjects enrolled	Hungary: 13
Country: Number of subjects enrolled	Japan: 44
Country: Number of subjects enrolled	Korea, Republic of: 35
Country: Number of subjects enrolled	Latvia: 12
Country: Number of subjects enrolled	Poland: 52
Worldwide total number of subjects	391
EEA total number of subjects	175

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	40
Adults (18-64 years)	332
From 65 to 84 years	19
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Subjects with age greater than or equal to (>=) 12 years with moderate to severe atopic dermatitis (AD) and a body weight of >=40 kilograms were enrolled in the study. Eligible subjects had an option to enter into a long-term extension (LTE) study after completing 12 weeks of treatment in this study.

Pre-assignment

Screening details:

This study was conducted from 29-June-2018 to 13-Aug-2019 at 106 sites in 13 countries.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Carer, Assessor, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	PF-04965842 100 mg

Arm description:

Subjects were randomized to receive a tablet of PF-04965842 (abrocitinib) 100 milligrams (mg) and a tablet of matching placebo orally once daily for 12 weeks. Subjects who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.

Arm type	Experimental
Investigational medicinal product name	Abrocitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received 100 milligram (mg) tablet orally once daily for 12 weeks

Arm title	PF-04965842 200 mg

Arm description:

Subjects were randomized to receive PF-04965842 200 mg (2 tablets of 100 mg each) orally once daily for 12 weeks. Subjects who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.

Arm type	Experimental
Investigational medicinal product name	Abrocitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received 200 mg (2 tablets of 100 mg each) orally once daily for 12 weeks.

Arm title	Placebo

Arm description:

Subjects were randomized to receive 2 tablets of placebo matched to PF-04965842 100 mg orally once daily for 12 weeks. Subjects who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.

Arm type	Placebo

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received 2 tablets of placebo matched to PF-04965842 100 mg orally once daily for 12 weeks.

Number of subjects in period 1	PF-04965842 100 mg	PF-04965842 200 mg	Placebo
Started	158	155	78
Completed	137	141	52
Not completed	21	14	26
Protocol Deviation	1	1	1
Other than specified	2	2	-
Lack of efficacy	5	4	7
Adverse event, serious fatal	1	-	-
Adverse event, non-fatal	5	5	8
Consent withdrawn by subject	6	1	9
Lost to follow-up	1	1	1

Baseline characteristics

Reporting groups	
Reporting group title	PF-04965842 100 mg
Reporting group description:	
Subjects were randomized to receive a tablet of PF-04965842 (abrocitinib) 100 milligrams (mg) and a tablet of matching placebo orally once daily for 12 weeks. Subjects who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.	
Reporting group title	PF-04965842 200 mg
Reporting group description:	
Subjects were randomized to receive PF-04965842 200 mg (2 tablets of 100 mg each) orally once daily for 12 weeks. Subjects who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.	
Reporting group title	Placebo
Reporting group description:	
Subjects were randomized to receive 2 tablets of placebo matched to PF-04965842 100 mg orally once daily for 12 weeks. Subjects who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.	

Reporting group values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo
Number of subjects	158	155	78
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	17	15	8
Adults (18-64 years)	130	133	69
From 65-84 years	11	7	1
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	37.4	33.5	33.4
standard deviation	± 15.8	± 14.7	± 13.8
Sex: Female, Male Units: Subjects			
Female	64	67	31
Male	94	88	47
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	3	4	2
Not Hispanic or Latino	154	150	73
Unknown or Not Reported	1	1	3
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0

Asian	46	54	29
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	9	6	6
White	101	91	40
More than one race	1	2	1
Unknown or Not Reported	1	2	2

Reporting group values	Total		
Number of subjects	391		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	40		
Adults (18-64 years)	332		
From 65-84 years	19		
85 years and over	0		
Age Continuous			
Units: years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male			
Units: Subjects			
Female	162		
Male	229		
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	9		
Not Hispanic or Latino	377		
Unknown or Not Reported	5		
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0		
Asian	129		
Native Hawaiian or Other Pacific Islander	0		
Black or African American	21		
White	232		
More than one race	4		
Unknown or Not Reported	5		

End points

End points reporting groups

Reporting group title	PF-04965842 100 mg

Reporting group description:

Subjects were randomized to receive a tablet of PF-04965842 (abrocitinib) 100 milligrams (mg) and a tablet of matching placebo orally once daily for 12 weeks. Subjects who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.

Reporting group title	PF-04965842 200 mg

Reporting group description:

Subjects were randomized to receive PF-04965842 200 mg (2 tablets of 100 mg each) orally once daily for 12 weeks. Subjects who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.

Reporting group title	Placebo

Reporting group description:

Subjects were randomized to receive 2 tablets of placebo matched to PF-04965842 100 mg orally once daily for 12 weeks. Subjects who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.

Primary: Percentage of Subjects Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12

End point title	Percentage of Subjects Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12

End point description:

IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). Scores: 0=clear, no inflammatory signs of AD; 1=almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2=mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3=moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4=severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Assessment excluded soles, palms and scalp. Full analysis set included all randomized subjects who received at least 1 dose of study drug. Number of Subjects Analysed signifies subjects evaluable for this endpoint.

End point type	Primary

End point timeframe:

Baseline, Week 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	155	155	77	
Units: percentage of subjects				
number (confidence interval 95%)	28.4 (21.3 to 35.5)	38.1 (30.4 to 45.7)	9.1 (2.7 to 15.5)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

The estimate and confidence interval (CI) for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0008 [1]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	19.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.6
upper limit	29

Notes:

[1] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [2]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	28.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.6
upper limit	38.8

Notes:

[2] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Primary: Percentage of Subjects Achieving Eczema Area and Severity Index Response of >=75 Percent (%) Improvement (EASI-75) From Baseline at Week 12

End point title	Percentage of Subjects Achieving Eczema Area and Severity

	Index Response of >=75 Percent (%) Improvement (EASI-75) From Baseline at Week 12

End point description:

EASI evaluates severity of subject's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity scored on 4-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (>0 to <10%), 2 (10 to <30%), 3 (30 to <50%), 4 (50 to <70%), 5 (70 to <90%) and 6 (90 to 100%). Total EASI score=0.1*Ah*(Eh+Ih+Exh+Lh)+0.2*Au (Eu+Iu+ExU+Lu)+0.3*At*(Et+It+Ext+Lt)+0.4*Al (El+Il+Exl+Ll); A=EASI area score; E=erythema; I=induration/papulation; Ex=excoriation; L= lichenification; h=head and neck; u=upper limbs; t=trunk; l=lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analysed" signifies subjects evaluable for this endpoint.

End point type	Primary

End point timeframe:

Baseline, Week 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	155	154	77	
Units: percentage of subjects				
number (confidence interval 95%)	44.5 (36.7 to 52.3)	61.0 (53.3 to 68.7)	10.4 (3.6 to 17.2)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [3]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	33.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	23.3
upper limit	44.4

Notes:

[3] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

The estimate and CI for difference were calculated based on the weighted average of difference for each

randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	231
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [4]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	50.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	40
upper limit	60.9

Notes:

[4] - P-value was adjusted by randomization strata (baseline disease severity and age category)

Secondary: Percentage of Subjects who Achieved at Least 4-Points Improvement From Baseline in the Numerical Rating Scale (NRS) for Severity of Pruritus at Weeks 2, 4, 8 and 12

End point title	Percentage of Subjects who Achieved at Least 4-Points Improvement From Baseline in the Numerical Rating Scale (NRS) for Severity of Pruritus at Weeks 2, 4, 8 and 12

End point description:

Subjects were asked to assess their worst pruritus/itching due to AD over the past 24 hours on an NRS scale ranged from 0 (no itching) to 10 (worst possible itching), where higher scores indicated greater severity. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	156	153	76	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 2	23.1 (16.5 to 29.7)	35.3 (27.7 to 42.9)	3.9 (0.0 to 8.3)	
Week 4	31.4 (24.1 to 38.7)	50.3 (42.4 to 58.2)	3.9 (0.0 to 8.3)	
Week 8	39.1 (31.4 to 46.8)	51.6 (43.7 to 59.6)	11.8 (4.6 to 19.1)	
Week 12	39.7 (32.1 to 47.4)	49.0 (41.1 to 56.9)	10.5 (3.6 to 17.4)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002 [5]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	19.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	11
upper limit	27.4

Notes:

[5] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	229
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [6]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	31.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	22.3
upper limit	40.2

Notes:

[6] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [7]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage

Point estimate	27.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.9
upper limit	36.2

Notes:

[7] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	229
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [8]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	46.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	37.2
upper limit	55.7

Notes:

[8] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [9]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	27.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	16.8
upper limit	38

Notes:

[9] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	229
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [10]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	39.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	28.9
upper limit	50.6

Notes:

[10] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [11]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	29.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.9
upper limit	39.6

Notes:

[11] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	229
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [12]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	38.6

Confidence interval	
level	95 %
sides	2-sided
lower limit	28.1
upper limit	49.1

Notes:

[12] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) Total Score at Week 12

End point title	Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) Total Score at Week 12

End point description:

PSAAD is a daily subject reported symptom electronic diary. Subjects rated their symptoms of AD over the past 24 hours, using 11 items (itchy skin, painful skin, dry skin, flaky skin, cracked skin, bumpy skin, red skin, discolored skin [lighter or darker], bleeding from skin, seeping or oozing fluid from skin [other than blood], and skin swelling). Subject had to think about all the areas of their body affected by their skin condition and chose the number that best described their experience for each of the 11 items, from 0 (no symptoms) to 10 (extreme symptoms), higher scores signified worse skin condition. Total PSAAD score = arithmetic mean of 11 items, 0 (no symptoms) to 10 (extreme symptoms), where higher score = worse skin condition. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analysed" signifies subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Baseline, Week 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	156	155	77	
Units: units on a scale				
least squares mean (confidence interval 95%)	-2.4 (-2.8 to -2.1)	-3.0 (-3.3 to -2.7)	-0.8 (-1.3 to -0.3)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category), baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.7
Confidence interval	

level	95 %
sides	2-sided
lower limit	-2.3
upper limit	-1.1

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category), baseline value and an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	232
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	-1.6

Secondary: Time to Achieve >=4 Points Improvement From Baseline in Numerical Rating Scale (NRS) for Severity of Pruritus

End point title	Time to Achieve >=4 Points Improvement From Baseline in Numerical Rating Scale (NRS) for Severity of Pruritus

End point description:

Subjects were asked to assess their worst itching/pruritus due to AD over the past 24 hours on an NRS scale ranged from 0 (no itching) to 10 (worst itch imaginable), where higher scores indicated greater severity. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "Number of Subjects Analysed" signifies subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Baseline up to Day 15

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	90[13]	110[14]	20[15]	
Units: days				
median (inter-quartile range (Q1-Q3))	58.0 (11.0 to 99999)	29.0 (8.0 to 87.0)	112.0 (58.0 to 99999)	

Notes:

[13] - Here, '99999' indicate that upper limit was not evaluable as too few events were observed.

[14] - Here, '99999' indicate that upper limit was not evaluable as too few events were observed.

[15] - Here, '99999' indicate that upper limit was not evaluable as too few events were observed.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving Eczema Area and Severity Index Response of >=75% Improvement (EASI-75) From Baseline at Weeks 2, 4 and 8

End point title	Percentage of Subjects Achieving Eczema Area and Severity Index Response of >=75% Improvement (EASI-75) From Baseline at Weeks 2, 4 and 8

End point description:

EASI evaluates severity of subjects AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity scored on 4-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (>0 to <10%), 2 (10 to <30%), 3 (30 to <50%), 4 (50 to <70%), 5 (70 to <90%) and 6 (90 to 100%). Total EASI score=0.1*Ah*(Eh+Ih+Exh+Lh)+0.2*Au*(Eu+Iu+ExU+Lu)+0.3*At*(Et+It+Ext+Lt)+0.4*Al*(El+Il+Exl+Ll); A=EASI area score; E=erythema; I=induration/papulation; Ex=excoriation; L= lichenification; h=head and neck; u=upper limbs; t=trunk; l=lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "n" signifies subjects evaluable for this endpoint at specified

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4 and 8

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	158	155	78	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 2 (n=157, 152, 76)	10.2 (5.5 to 14.9)	24.3 (17.5 to 31.2)	1.3 (0.0 to 3.9)	
Week 4 (n=155, 153, 77)	26.5 (19.5 to 33.4)	51.0 (43.1 to 58.9)	6.5 (1.0 to 12.0)	
Week 8 (n=157, 154, 78)	43.3 (35.6 to 51.1)	60.4 (52.7 to 68.1)	12.8 (5.4 to 20.2)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236

Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.015 [16]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	8.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.8
upper limit	14.9

Notes:

[16] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [17]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	22.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	15
upper limit	30.3

Notes:

[17] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0004 [18]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	20
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.9
upper limit	29

Notes:

[18] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [19]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	44.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	34.8
upper limit	53.8

Notes:

[19] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [20]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	30.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	19.7
upper limit	41.2

Notes:

[20] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority

P-value	< 0.0001 [21]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	47.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	36.8
upper limit	58

Notes:

[21] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects Achieving IGA Response of Clear (0) or Almost Clear (1) and >=2 points Improvement From Baseline at Weeks 2, 4 and 8

End point title	Percentage of Subjects Achieving IGA Response of Clear (0) or Almost Clear (1) and >=2 points Improvement From Baseline at Weeks 2, 4 and 8

End point description:

IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). Scores: 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Assessment excluded sole, palms and scalp. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "n" signifies the number of subjects evaluable at specified time points.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, and 8

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	158	155	78	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 2 (n=157, 152, 76)	5.1 (1.7 to 8.5)	14.5 (8.9 to 20.1)	0 (0.0 to 4.7)	
Week 4 (n=155, 153, 77)	14.2 (8.7 to 19.7)	33.3 (25.9 to 40.8)	1.3 (0.0 to 3.8)	
Week 8 (n=157, 154, 78)	22.3 (15.8 to 28.8)	37.7 (30.0 to 45.3)	10.3 (3.5 to 17.0)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0459 [22]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	5.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.2
upper limit	10

Notes:

[22] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0005 [23]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	14.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.8
upper limit	20.5

Notes:

[23] - P-value was adjusted by randomization strata (baseline disease severity and age category)

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0019 [24]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	12.9
Confidence interval	
level	95 %
sides	2-sided

lower limit	6.3
upper limit	19.4

Notes:

[24] - P-value was adjusted by randomization strata (baseline disease severity and age category)

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [25]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	31.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	23.6
upper limit	39.9

Notes:

[25] - P-value was adjusted by randomization strata (baseline disease severity and age category)

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0246 [26]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	11.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.4
upper limit	21.4

Notes:

[26] - P-value was adjusted by randomization strata (baseline disease severity and age category)

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233

Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [27]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	26.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	17
upper limit	36.9

Notes:

[27] - P-value was adjusted by randomization strata (baseline disease severity and age category)

Secondary: Percentage of Subjects Achieving Investigator's Global Assessment (IGA) Response of Clear (0) at Week 2, 4, 8 and 12

End point title	Percentage of Subjects Achieving Investigator's Global Assessment (IGA) Response of Clear (0) at Week 2, 4, 8 and 12

End point description:

IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). Scores: 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, induration lichenification, excoriation, and no oozing; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Assessment excluded soles, palms and scalp. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "n" signifies the number of subjects evaluable at specified time points.

End point type	Secondary

End point timeframe:

Weeks 2, 4, 8, and 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	158	155	78	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 2 (n=157, 152, 76)	0 (0.0 to 2.3)	2.0 (0.0 to 4.2)	0 (0.0 to 4.7)	
Week 4 (n=155, 153, 77)	1.9 (0.0 to 4.1)	4.6 (1.3 to 7.9)	0 (0.0 to 4.7)	
Week 8 (n=157, 154, 78)	1.3 (0.0 to 3.0)	4.5 (1.3 to 7.8)	0 (0.0 to 4.6)	
Week 12 (n=155, 155, 77)	5.2 (1.7 to 8.6)	6.5 (2.6 to 10.3)	0 (0.0 to 4.7)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.7
upper limit	3.7

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2262 [28]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	6.1

Notes:

[28] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2223 [29]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	1.9

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	6.1

Notes:

[29] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0597 [30]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	4.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	9.2

Notes:

[30] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3207 [31]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	5.2

Notes:

[31] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0586 [32]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	4.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	9.2

Notes:

[32] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0419 [33]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	5.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.3
upper limit	10.1

Notes:

[33] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0244 [34]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	6.3
Confidence interval	

level	95 %
sides	2-sided
lower limit	1.2
upper limit	11.4

Notes:

[34] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects Achieving Eczema Area and Severity Index Response of >=50% Improvement (EASI-50) From Baseline at Weeks 2, 4, 8 and 12

End point title	Percentage of Subjects Achieving Eczema Area and Severity Index Response of >=50% Improvement (EASI-50) From Baseline at Weeks 2, 4, 8 and 12

End point description:

EASI evaluates severity of subjects AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity scored on 4-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (>0 to <10%), 2 (10 to <30%), 3 (30 to <50%), 4 (50 to <70%), 5 (70 to <90%) and 6 (90 to 100%). Total EASI score=0.1*Ah*(Eh+Ih+Exh+Lh)+0.2*Au*(Eu+Iu+ExU+Lu)+0.3*At*(Et+It+Ext+Lt)+0.4*Al*(El+Il+Exl+Ll); A=EASI area score; E=erythema; I=induration/papulation; Ex=excoriation; L= lichenification; h=head and neck; u=upper limbs; t=trunk; l=lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "n" signifies the number of subjects evaluable at specified

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	158	155	78	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 2 (n=157, 152, 76)	35.7 (28.2 to 43.2)	55.3 (47.4 to 63.2)	10.5 (3.6 to 17.4)	
Week 4 (n=155, 153, 77)	58.7 (51.0 to 66.5)	78.4 (71.9 to 84.9)	28.6 (18.5 to 38.7)	
Week 8 (n=157, 154, 78)	66.2 (58.8 to 73.6)	82.5 (76.5 to 88.5)	34.6 (24.1 to 45.2)	
Week 12 (n=155, 154, 77)	68.4 (61.1 to 75.7)	79.9 (73.5 to 86.2)	19.5 (10.6 to 28.3)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified

Analysis type	superiority
P-value	< 0.0001 [35]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	25
Confidence interval	
level	95 %
sides	2-sided
lower limit	14.8
upper limit	35.2

Notes:

[35] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [36]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	44.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	33.9
upper limit	54.6

Notes:

[36] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [37]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	30.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	17.5
upper limit	42.8

Notes:

[37] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [38]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	49.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	37.8
upper limit	61.7

Notes:

[38] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [39]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	31.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.8
upper limit	44.3

Notes:

[39] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority

P-value	< 0.0001 [40]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	47.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	35.7
upper limit	59.6

Notes:

[40] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [41]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	48.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	37.2
upper limit	60.1

Notes:

[41] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [42]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	60.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	49.1
upper limit	71

Notes:

[42] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects Achieving Eczema Area and Severity Index Response of >=90% Improvement (EASI-90) From Baseline at Weeks 2, 4, 8 and 12

End point title	Percentage of Subjects Achieving Eczema Area and Severity Index Response of >=90% Improvement (EASI-90) From Baseline at Weeks 2, 4, 8 and 12

End point description:

EASI evaluates severity of subjects AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity scored on 4-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (>0 to <10%), 2 (10 to <30%), 3 (30 to <50%), 4 (50 to <70%), 5 (70 to <90%) and 6 (90 to 100%). Total EASI score=0.1*Ah*(Eh+Ih+Exh+Lh)+0.2*Au*(Eu+Iu+ExU+Lu)+0.3*At*(Et+It+Ext+Lt)+0.4*Al*(El+Il+Exl+Ll); A=EASI area score; E=erythema; I=induration/papulation; Ex=excoriation; L= lichenification; h=head and neck; u=upper limbs; t=trunk; l=lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "n" signifies the number of subjects evaluable at specified

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	158	155	78	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 2 (n= 157, 152, 76)	2.5 (0.1 to 5.0)	9.2 (4.6 to 13.8)	0 (0.0 to 4.7)	
Week 4 (n= 155, 153, 77)	9.7 (5.0 to 14.3)	22.9 (16.2 to 29.5)	0 (0.0 to 4.7)	
Week 8 (n= 157, 154, 78)	17.2 (11.3 to 23.1)	34.4 (26.9 to 41.9)	2.6 (0.0 to 6.1)	
Week 12 (n= 155, 154, 77)	23.9 (17.2 to 30.6)	37.7 (30.0 to 45.3)	3.9 (0.0 to 8.2)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1623 [43]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage

Point estimate	2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.7
upper limit	6.8

Notes:

[43] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.007 [44]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.4
upper limit	14.7

Notes:

[44] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0049 [45]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	9.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	4
upper limit	15.4

Notes:

[45] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [46]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	22.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	15.5
upper limit	30.2

Notes:

[46] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0013 [47]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	14.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.2
upper limit	22

Notes:

[47] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [48]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	31.6

Confidence interval	
level	95 %
sides	2-sided
lower limit	23.1
upper limit	40.1

Notes:

[48] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0001 [49]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	20.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	11.9
upper limit	28.3

Notes:

[49] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	33.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	24.6
upper limit	42.5

Secondary: Percentage of Subjects Achieving Eczema Area and Severity Index Response of 100% Improvement (EASI-100) From Baseline at Weeks 2, 4, 8 and 12

End point title	Percentage of Subjects Achieving Eczema Area and Severity

	Index Response of 100% Improvement (EASI-100) From Baseline at Weeks 2, 4, 8 and 12

End point description:

EASI evaluates severity of subjects AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity scored on 4-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (>0 to <10%), 2 (10 to <30%), 3 (30 to <50%), 4 (50 to <70%), 5 (70 to <90%) and 6 (90 to 100%). Total EASI score=0.1*Ah*(Eh+Ih+Exh+Lh)+0.2*Au*(Eu+Iu+ExU+Lu)+0.3*At*(Et+It+Ext+Lt)+0.4*Al*(El+Il+Exl+Ll); A=EASI area score; E=erythema; I=induration/papulation; Ex=excoriation; L= lichenification; h=head and neck; u=upper limbs; t=trunk; l=lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD. Full analysis set included all randomized subjects who received at least 1 dose of study medication. Here, "n" signifies the number of subjects evaluable at specified

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	158	155	78	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 2 (n= 157, 152, 76)	0 (0.0 to 2.3)	1.3 (0.0 to 3.1)	0 (0.0 to 4.7)	
Week 4 (n= 155, 153, 77)	1.3 (0.0 to 3.1)	3.9 (0.8 to 7.0)	0 (0.0 to 4.7)	
Week 8 (n= 157, 154, 78)	1.3 (0.0 to 3.0)	3.9 (0.8 to 7.0)	0 (0.0 to 4.6)	
Week 12 (n= 155, 154, 77)	5.2 (1.7 to 8.6)	7.1 (3.1 to 11.2)	0 (0.0 to 4.7)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0 [50]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.7
upper limit	3.7

Notes:

[50] - P-value could not be calculated since percentage of subjects with events was 0.

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3261 [51]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	5.3

Notes:

[51] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3207 [52]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	5.3

Notes:

[52] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority

P-value	= 0.081 [53]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	3.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	8.5

Notes:

[53] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3207 [54]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	5.2

Notes:

[54] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.081 [55]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.7
upper limit	8.4

Notes:

[55] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0419 [56]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	5.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.3
upper limit	10.1

Notes:

[56] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.018 [57]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	7
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.8
upper limit	12.2

Notes:

[57] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 2, 4, 8 and 12

End point title	Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 2, 4, 8 and 12

End point description:

EASI evaluates severity of subjects AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity scored on 4-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (>0 to <10%), 2 (10 to <30%), 3 (30 to <50%), 4 (50 to <70%), 5 (70 to <90%) and 6 (90 to 100%).

Total EASI score=0.1*Ah*(Eh+Ih+Exh+Lh)+0.2*Au*(Eu+Iu+ExU+Lu)+0.3*At*(Et+It+Ext+Lt)+0.4*Al*(El+Il+Exl+Ll); A=EASI area score; E=erythema; I=induration/papulation; Ex=excoriation; L= lichenification; h=head and neck; u=upper limbs; t=trunk; l=lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD. Full analysis set included all randomized subjects who received

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	158	155	78	
Units: percent change				
least squares mean (confidence interval 95%)				
Change at Week 2	-39.2 (-43.8 to -34.7)	-51.3 (-55.9 to -46.7)	-9.0 (-15.4 to -2.5)	
Change at Week 4	-54.3 (-59.1 to -49.5)	-69.0 (-73.7 to -64.2)	-24.4 (-31.1 to -17.7)	
Change at Week 8	-59.5 (-65.0 to -54.0)	-73.2 (-78.7 to -67.7)	-33.0 (-41.1 to -25.0)	
Change at Week 12	-60.0 (-66.5 to -53.6)	-73.3 (-79.7 to -66.9)	-28.6 (-38.4 to -18.8)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-30.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-38.1
upper limit	-22.3

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-42.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-50.3
upper limit	-34.4

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-29.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-38.1
upper limit	-21.7

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean

Point estimate	-44.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-52.8
upper limit	-36.3

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-26.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-36.2
upper limit	-16.7

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-40.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-50
upper limit	-30.4

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-31.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-43.1
upper limit	-19.7

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-44.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-56.4
upper limit	-33

Secondary: Change From Baseline in the Percentage Body Surface Area (%BSA) Affected at Week 2, 4, 8, and 12

End point title	Change From Baseline in the Percentage Body Surface Area (%BSA) Affected at Week 2, 4, 8, and 12

End point description:

4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated by handprint method. Number of handprints fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was

calculated as = total number of handprints in a body region * % surface area equivalent to 1 handprint. Overall % BSA calculated: arithmetic mean of % BSA of all 4 body regions, ranges from 0 to 100%, higher values = greater severity of AD. Full analysis set included all randomized subjects who received at least 1 dose of study medication.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	158	155	78	
Units: Percentage of BSA				
least squares mean (confidence interval 95%)				
Week 2	-27.8 (-33.0 to -22.6)	-35.4 (-40.6 to -30.2)	-1.3 (-8.7 to 6.0)	
Week 4	-45.0 (-50.4 to -39.6)	-55.7 (-61.1 to -50.3)	-15.3 (-22.9 to -7.7)	
Week 8	-53.4 (-60.0 to -46.8)	-61.1 (-67.7 to -54.5)	-20.5 (-30.1 to -10.9)	
Week 12	-56.4 (-63.1 to -49.6)	-65.0 (-71.7 to -58.3)	-16.8 (-26.9 to -6.6)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-26.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-35.5
upper limit	-17.5

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-34.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-43.1
upper limit	-25.1

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-29.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-39
upper limit	-20.4

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean

Point estimate	-40.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-49.8
upper limit	-31.1

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-32.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-44.6
upper limit	-21.2

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-40.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-52.2
upper limit	-28.9

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-39.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-51.8
upper limit	-27.4

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-48.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-60.4
upper limit	-36

Secondary: Percentage of Subjects With Percentage Body Surface Area (%BSA) (From EASI) < 5% at Weeks 2, 4, 8 and 12

End point title	Percentage of Subjects With Percentage Body Surface Area (%BSA) (From EASI) < 5% at Weeks 2, 4, 8 and 12

End point description:

4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. SA of body region: 1 handprint was equal to 10% for head and neck, 5% for upper limb, 3.33% for trunk and 2.5% for lower limb. % BSA for a body region was calculated as = total number of

handprints in a body region * % surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranges from 0 to 100%, with higher values = greater severity of AD. Full analysis set included all randomized subjects who received at least 1 dose of study medication. "n" = the number of subjects evaluable at specified time points.

End point type	Secondary

End point timeframe:

Weeks 2, 4, 8, and 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	158	155	78	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 2 (n=157, 152, 76)	1.9 (0.0 to 4.1)	5.9 (2.2 to 9.7)	0 (0.0 to 4.7)	
Week 4 (n=155, 153, 77)	6.5 (2.6 to 10.3)	17.0 (11.0 to 22.9)	0 (0.0 to 4.7)	
Week 8 (n=157, 154, 78)	15.9 (10.2 to 21.6)	27.3 (20.2 to 34.3)	1.3 (0.0 to 3.8)	
Week 12 (n=155, 154, 77)	22.6 (16.0 to 29.2)	34.4 (26.9 to 41.9)	3.9 (0.0 to 8.2)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2353 [58]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	6

Notes:

[58] - P-value was adjusted by randomization strata (baseline disease severity and age category)

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo

Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0332 [59]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	5.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8
upper limit	10.8

Notes:

[59] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0227 [60]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	6.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.4
upper limit	11.6

Notes:

[60] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0001 [61]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	16.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.1

upper limit	23.5

Notes:

[61] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0008 [62]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	14.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.7
upper limit	21.3

Notes:

[62] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [63]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	25.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.1
upper limit	33.4

Notes:

[63] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified

Analysis type	superiority
P-value	= 0.0003 [64]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	18.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.5
upper limit	26.5

Notes:

[64] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	30.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	21.4
upper limit	39

Secondary: Percentage of Subjects Achieving Atopic Dermatitis (SCORAD) Response >=50% Improvement From Baseline at Week 2, 4, 8 and 12

End point title	Percentage of Subjects Achieving Atopic Dermatitis (SCORAD) Response >=50% Improvement From Baseline at Week 2, 4, 8 and 12

End point description:

SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA of whole BSA - head and neck 9%; upper limbs 9%; lower limbs 18%; anterior trunk 18%; back 18%; 1% for genitals. The score was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; skin thickening; dryness) was assessed as none=0, mild=1, moderate=2,severe=3. The severity scores were summed to give B (0-18). Subjective symptoms (C): pruritus and sleep, each of these 2 were scored by subject/caregiver using visual analogue scale (VAS) where 0=no itch/ sleeplessness and 10=the worst imaginable itch/sleeplessness, higher scores=worse symptoms. Scores for itch and sleeplessness were added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7*B/2 + C; range from 0 to 103; higher values of SCORAD=worse. Full analysis set population included. Number Analyzed = number of subjects evaluable at the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	158	155	78	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 2 (n= 157, 152, 76)	12.7 (7.5 to 18.0)	32.9 (25.4 to 40.4)	0 (0.0 to 4.7)	
Week 4 (n= 155, 153, 77)	36.1 (28.6 to 43.7)	60.8 (53.0 to 68.5)	7.8 (1.8 to 13.8)	
Week 8 (n= 157, 154, 78)	43.3 (35.6 to 51.1)	61.7 (54.0 to 69.4)	15.4 (7.4 to 23.4)	
Week 12 (n= 155, 155, 76)	49.0 (41.2 to 56.9)	62.6 (55.0 to 70.2)	12.8 (5.4 to 20.2)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0011 [65]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	12.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.5
upper limit	18.9

Notes:

[65] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [66]
Method	Cochran-Mantel-Haenszel

Parameter estimate	Difference in Percentage
Point estimate	32.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	24.6
upper limit	40.6

Notes:

[66] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [67]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	28.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.5
upper limit	38.2

Notes:

[67] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [68]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	52.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	43.2
upper limit	62.5

Notes:

[68] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [69]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	28
Confidence interval	
level	95 %
sides	2-sided
lower limit	17
upper limit	39

Notes:

[69] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [70]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	46.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	35.2
upper limit	57.1

Notes:

[70] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [71]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage

Point estimate	36.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	25.4
upper limit	47.1

Notes:

[71] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [72]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	49.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	38.9
upper limit	60.3

Notes:

[72] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Percentage of Subjects Achieving Atopic Dermatitis (SCORAD) Response >=75% Improvement From Baseline at Week 2, 4, 8 and 12

End point title	Percentage of Subjects Achieving Atopic Dermatitis (SCORAD) Response >=75% Improvement From Baseline at Week 2, 4, 8 and 12

End point description:

SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA of whole BSA - head and neck 9%; upper limbs 9%; lower limbs 18%; anterior trunk 18%; back 18%; 1% for genitals. The score was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; skin thickening; dryness) was assessed as none=0, mild=1, moderate=2,severe=3. The severity scores were summed to give B (0-18). Subjective symptoms (C): pruritus and sleep, each of these 2 were scored by subject/caregiver using visual analogue scale (VAS) where 0=no itch/ sleeplessness and 10=the worst imaginable itch/sleeplessness, higher scores=worse symptoms. Scores for itch and sleeplessness were added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7*B/2 + C; range from 0 to 103; higher values of SCORAD=worse. Full analysis set population included. Number Analyzed = number of subjects evaluable at the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	158	155	78	
Units: percentage of subjects				
number (confidence interval 95%)				
Week 2 (n= 157, 152, 76)	1.9 (0.0 to 4.1)	5.3 (1.7 to 8.8)	0 (0.0 to 4.7)	
Week 4 (n= 155, 153, 77)	7.1 (3.1 to 11.1)	17.6 (11.6 to 23.7)	0 (0.0 to 4.7)	
Week 8 (n= 157, 154, 78)	11.5 (6.5 to 16.4)	26.0 (19.0 to 32.9)	0 (0.0 to 4.6)	
Week 12 (n= 155, 155, 78)	18.7 (12.6 to 24.8)	30.3 (23.1 to 37.6)	2.6 (0.0 to 6.1)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2261 [73]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	6

Notes:

[73] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 2: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0451 [74]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	5.2
Confidence interval	
level	95 %
sides	2-sided

lower limit	0.3
upper limit	10

Notes:

[74] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0171 [75]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	7
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.8
upper limit	12.3

Notes:

[75] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 4: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [76]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	17.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.9
upper limit	24.5

Notes:

[76] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236

Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0018 [77]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	11.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.5
upper limit	17.5

Notes:

[77] - P-value was adjusted by randomization strata (baseline disease severity and age category)

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 8: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [78]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	25.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.3
upper limit	33.1

Notes:

[78] - P-value was adjusted by randomization strata (baseline disease severity and age category)

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0005 [79]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	16.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.8
upper limit	23.6

Notes:

[79] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 12: The estimate and CI for difference were calculated based on the weighted average of difference for each randomization stratum using the normal approximation of binomial proportions.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [80]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in Percentage
Point estimate	27.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	19.3
upper limit	35.8

Notes:

[80] - P-value was adjusted by randomization strata (baseline disease severity and age category).

Secondary: Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analogue Scale (VAS) of Itch at Weeks 2, 4, 8 and 12

End point title	Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analogue Scale (VAS) of Itch at Weeks 2, 4, 8 and 12

End point description:

SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA of whole BSA - head and neck 9%; upper limbs 9%; lower limbs 18%; anterior trunk 18%; back 18%; 1% for genitals. The score was added to determine A (0-100). Severity (B): severity sign (erythema; edema; skin thickening; dryness) was assessed as none=0, mild=1, moderate=2, severe=3. The severity scores summed to give B (0-18). Subjective symptoms (C): pruritus and sleep, these 2 were scored by subject using visual analogue scale (VAS) where 0=no itch/ sleeplessness and 10=the worst imaginable itch/sleeplessness, higher scores=worse symptoms. Scores for itch and sleeplessness summed to give 'C' (0-20). The SCORAD was calculated: A/5 + 7*B/2 + C; range from 0 to 103; higher values of SCORAD=worse. This endpoint was not analyzed as planned because the severity assessment of itch was measured more effectively in other endpoints, such as the numerical rating scale.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0[81]	0[82]	0[83]	
Units: units on a scale				

Notes:

[81] - Endpoint was not analyzed as itch was measured more effectively in other endpoints using the NRS.

[82] - Endpoint was not analyzed as itch was measured more effectively in other endpoints using the NRS.
[83] - Endpoint was not analyzed as itch was measured more effectively in other endpoints using the NRS.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analogue Scale (VAS) Sleep Loss at Weeks 2, 4, 8 and 12

End point title	Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analogue Scale (VAS) Sleep Loss at Weeks 2, 4, 8 and 12

End point description:

SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA of whole BSA - head and neck 9%; upper limbs 9%; lower limbs 18%; anterior trunk 18%; back 18%; 1% for genitals. The score was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; skin thickening; dryness) was assessed as none=0, mild=1, moderate=2,severe=3. The severity scores were summed to give B (0-18). Subjective symptoms (C): pruritus and sleep, each of these 2 were scored by subject/caregiver using visual analogue scale (VAS) where 0=no itch/ sleeplessness and 10=the worst imaginable itch/sleeplessness, higher scores=worse symptoms. Scores for itch and sleeplessness were added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7*B/2 + C; range from 0 to 103; higher values of SCORAD=worse. Full analysis population set included. Number Analyzed = number of subjects evaluable at the specified time points.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	158	155	78	
Units: units on a scale				
least squares mean (confidence interval 95%)				
Change at Week 2 (n= 155, 151, 76)	-1.9 (-2.2 to -1.5)	-2.9 (-3.3 to -2.5)	-0.5 (-1.0 to 0.0)	
Change at Week 4 (n= 149, 151, 76)	-2.8 (-3.1 to -2.4)	-3.9 (-4.3 to -3.6)	-1.0 (-1.5 to -0.5)	
Change at Week 8 (n= 148, 149, 66)	-3.1 (-3.5 to -2.7)	-3.9 (-4.3 to -3.5)	-1.5 (-2.1 to -0.9)	
Change at Week 12 (n= 140, 146, 56)	-3.0 (-3.4 to -2.6)	-3.8 (-4.2 to -3.4)	-2.1 (-2.7 to -1.5)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 2: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category), baseline value and unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2
upper limit	-0.8

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 2: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category), baseline value and unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3
upper limit	-1.8

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 4: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category), baseline value and unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.8
Confidence interval	

level	95 %
sides	2-sided
lower limit	-2.4
upper limit	-1.2

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 4: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category), baseline value and unstructured covariance matrix

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.6
upper limit	-2.3

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 8: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category), baseline value and unstructured covariance matrix

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.3
upper limit	-0.9

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 8: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category), baseline value and unstructured covariance matrix

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-2.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.1
upper limit	-1.7

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Week 12: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category), baseline value and unstructured covariance matrix

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0164
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.7
upper limit	-0.2

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Week 12: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category), baseline value and unstructured covariance matrix

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-1.7
Confidence interval	
level	95 %
sides	2-sided

lower limit	-2.5
upper limit	-1

Secondary: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Total Score at Week 2, 4, 8 and 12

End point title	Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Total Score at Week 2, 4, 8 and 12

End point description:

SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA of whole BSA - head and neck 9%; upper limbs 9%; lower limbs 18%; anterior trunk 18%; back 18%; 1% for genitals. The score was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; skin thickening; dryness) was assessed as none=0, mild=1, moderate=2,severe=3. The severity scores were summed to give B (0-18). Subjective symptoms (C): pruritus and sleep, each of these 2 were scored by subject/caregiver using visual analogue scale (VAS) where 0=no itch/ sleeplessness and 10=the worst imaginable itch/sleeplessness, higher scores=worse symptoms. Scores for itch and sleeplessness were added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7*B/2 + C; range from 0 to 103; higher values of SCORAD=worse. Full analysis population set included.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, and 12

End point values	PF-04965842 100 mg	PF-04965842 200 mg	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	158	155	78	
Units: percent change				
least squares mean (confidence interval 95%)				
Change at Week 2	-27.2 (-30.5 to -23.9)	-38.5 (-41.8 to -35.1)	-6.3 (-11.0 to -1.6)	
Change at Week 4	-38.9 (-42.6 to -35.1)	-53.1 (-56.9 to -49.4)	-17.2 (-22.5 to -12.0)	
Change at Week 8	-42.6 (-46.7 to -38.4)	-56.7 (-60.9 to -52.6)	-23.1 (-29.2 to -17.1)	
Change at Week 12	-45.8 (-50.9 to -40.7)	-56.2 (-61.2 to -51.1)	-22.7 (-30.4 to -15.1)	

Statistical analyses

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority

P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-20.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.6
upper limit	-15.1

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Change at Week 2: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-32.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-37.9
upper limit	-26.4

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-21.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-28.1
upper limit	-15.2

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Change at Week 4: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-35.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-42.3
upper limit	-29.4

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-19.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.8
upper limit	-12.1

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Change at Week 8: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo

Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-33.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-41
upper limit	-26.3

Statistical analysis title	PF-04965842 100 mg Versus Placebo

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 100 mg v Placebo
Number of subjects included in analysis	236
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-23.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-32.3
upper limit	-13.9

Statistical analysis title	PF-04965842 200 mg Versus Placebo

Statistical analysis description:

Change at Week 12: MMRM contained fixed factors of treatment, visit, treatment by visit interaction, randomization strata (baseline disease severity and age category) and baseline value and used an unstructured covariance matrix.

Comparison groups	PF-04965842 200 mg v Placebo
Number of subjects included in analysis	233
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Difference in LS mean
Point estimate	-33.4
Confidence interval	
level	95 %
sides	2-sided

lower limit	-42.6
upper limit	-24.3

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to Week 16

Adverse event reporting additional description:

Same event may appear as adverse event (AE) and serious AE, what is presented are distinct events. Event may be categorized as serious in 1 subject and as nonserious in another subject or 1 subject may have experienced both serious and nonserious event during study.

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	22.0

Reporting groups

Reporting group title	PF-04965842 100 mg

Reporting group description:

Subjects were randomized to receive a tablet of PF-04965842 (abrocitinib) 100 milligrams (mg) and a tablet of matching placebo orally once daily for 12 weeks. Subjects who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.

Reporting group title	Placebo

Reporting group description:

Subjects were randomized to receive 2 tablets of placebo matched to PF-04965842 100 mg orally once daily for 12 weeks. Subjects who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.

Reporting group title	PF-04965842 200 mg

Reporting group description:

Subjects were randomized to receive PF-04965842 200 mg (2 tablets of 100 mg each) orally once daily for 12 weeks. Subjects who discontinued early from treatment or who were not eligible for LTE study, were followed up to 4 weeks after last dose of study drug.

Serious adverse events	PF-04965842 100 mg	Placebo	PF-04965842 200 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 158 (3.16%)	1 / 78 (1.28%)	2 / 155 (1.29%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Femoral neck fracture			
subjects affected / exposed	0 / 158 (0.00%)	0 / 78 (0.00%)	1 / 155 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic shock			
subjects affected / exposed	0 / 158 (0.00%)	0 / 78 (0.00%)	1 / 155 (0.65%)
occurrences causally related to	0 / 0	0 / 0	0 / 1

treatment / all			
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Sudden death			
subjects affected / exposed	1 / 158 (0.63%)	0 / 78 (0.00%)	0 / 155 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	1 / 158 (0.63%)	0 / 78 (0.00%)	0 / 155 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Eczema herpeticum			
subjects affected / exposed	0 / 158 (0.00%)	1 / 78 (1.28%)	0 / 155 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpangina			
subjects affected / exposed	1 / 158 (0.63%)	0 / 78 (0.00%)	0 / 155 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis bacterial			
subjects affected / exposed	1 / 158 (0.63%)	0 / 78 (0.00%)	0 / 155 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 158 (0.63%)	0 / 78 (0.00%)	0 / 155 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	1 / 158 (0.63%)	0 / 78 (0.00%)	0 / 155 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal skin infection			

subjects affected / exposed	0 / 158 (0.00%)	1 / 78 (1.28%)	0 / 155 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	PF-04965842 100 mg	Placebo	PF-04965842 200 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	56 / 158 (35.44%)	22 / 78 (28.21%)	52 / 155 (33.55%)
Nervous system disorders			
Headache			
subjects affected / exposed	9 / 158 (5.70%)	2 / 78 (2.56%)	12 / 155 (7.74%)
occurrences (all)	10	4	16
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	12 / 158 (7.59%)	2 / 78 (2.56%)	22 / 155 (14.19%)
occurrences (all)	13	2	28
Vomiting			
subjects affected / exposed	2 / 158 (1.27%)	1 / 78 (1.28%)	8 / 155 (5.16%)
occurrences (all)	2	1	9
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	2 / 158 (1.27%)	0 / 78 (0.00%)	9 / 155 (5.81%)
occurrences (all)	2	0	9
Dermatitis atopic			
subjects affected / exposed	9 / 158 (5.70%)	12 / 78 (15.38%)	6 / 155 (3.87%)
occurrences (all)	9	13	7
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	20 / 158 (12.66%)	5 / 78 (6.41%)	12 / 155 (7.74%)
occurrences (all)	20	5	12
Upper respiratory tract infection			
subjects affected / exposed	14 / 158 (8.86%)	3 / 78 (3.85%)	5 / 155 (3.23%)
occurrences (all)	16	4	6

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported